Phase 2 study of TriRima for treatment resistant depression
CeNeRx BioPharma reported that it has initiated a Phase 2 trial of TriRima as monotherapy for treatment resistant depression.
Mood Disorders
Phase 2b study of RG2417 for the treatment of bipolar depression
Repligen reported that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417 in patients with bipolar depression.
Beyaz oral contraceptive that raises folate levels approved
The FDA has approved Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets, from Bayer HealthCare), an oral contraceptive that raises folate levels.
Phase 2b study of Serdaxin for major depressive disorder (MDD)
Rexahn announced that it has submitted a Phase 2b protocol to the FDA for the study of Serdaxin for the treatment of major depressive disorder (MDD).
FDA warns of aseptic meningitis risk with Lamictal
The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.
Oleptro available for major depressive disorder
Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.
FDA Video: Caution on Zyprexa for Adolescents
The FDA is recommending that healthcare professionals use caution when considering Zyprexa (olanzapine) for treating adolescents 13 to 17 years old for schizophrenia and bipolar disorder.
Phase 3 study of TC-5214 for major depressive disorder (MDD)
AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).
